Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic.
COVID-19
Corona virus
Mitigation impact
Public health
Risk mitigation measures
SARS-CoV-2
Journal
Safety science
ISSN: 0925-7535
Titre abrégé: Saf Sci
Pays: Netherlands
ID NLM: 9114980
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
09
04
2020
accepted:
10
04
2020
pubmed:
17
4
2020
medline:
17
4
2020
entrez:
17
4
2020
Statut:
ppublish
Résumé
This paper presents an analysis of risk mitigation measures taken by countries around the world facing the current COVID-19 outbreak. In light of the current pandemic the authors collated and clustered (using harmonised terminology) the risk mitigation measures taken around the globe in the combat to contain, and since March 11, 2020, to limit the spread of the SARS-CoV-2 virus known to cause the Coronavirus disease 2019 (COVID-19). This overview gathers lessons learnt, providing an update on the current knowledge for authorities, sectors and first responders on the effectiveness of said measures, and may allow enhanced prevention, preparedness and response for future outbreaks. Various measures such as mobility restrictions, physical distancing, hygienic measures, socio-economic restrictions, communication and international support mechanisms have been clustered and are reviewed in terms of the nature of the actions taken and their qualitative early-perceived impact. At the time of writing, it is still too premature to express the quantitative effectiveness of each risk mitigation cluster, but it seems that the best mitigation results are reported when applying a combination of voluntary and enforceable measures.
Identifiants
pubmed: 32296266
doi: 10.1016/j.ssci.2020.104773
pii: S0925-7535(20)30170-3
pii: 104773
pmc: PMC7158845
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104773Informations de copyright
© 2020 The Authors.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Respir Med. 2020 May;8(5):434-436
pubmed: 32203710
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Vaccine. 2011 Feb 11;29(8):1605-10
pubmed: 21211593
Int J Biol Sci. 2020 Mar 15;16(10):1686-1697
pubmed: 32226286
Int J Infect Dis. 2020 Apr;93:211-216
pubmed: 32145465
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD006207
pubmed: 21735402
PLoS One. 2006 Dec 20;1:e20
pubmed: 17183647
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Health Secur. 2020 Jan/Feb;18(1):36-48
pubmed: 32078425
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet. 2020 Mar 21;395(10228):945
pubmed: 32142626
Environ Health Perspect. 2010 Nov;118(11):1507-14
pubmed: 20576580
Clin Microbiol Rev. 2004 Jan;17(1):136-73
pubmed: 14726459
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Microbiol Immunol Infect. 2020 Jun;53(3):365-367
pubmed: 32035811
J Bus Contin Emer Plan. 2020 Jan 1;13(4):298-312
pubmed: 32438951
Lancet Infect Dis. 2014 Oct;14(10):1001-10
pubmed: 25189351
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
Lancet Glob Health. 2020 Apr;8(4):e452-e453
pubmed: 32199105
N Engl J Med. 2020 Feb 20;382(8):760-762
pubmed: 31978944
Acad Emerg Med. 1998 Jun;5(6):618-24
pubmed: 9660290
J Infect. 2020 Jun;80(6):e32-e33
pubmed: 32209383
Ann Work Expo Health. 2020 Jun 24;64(5):461-464
pubmed: 32202635
Elife. 2020 Feb 24;9:
pubmed: 32091395
Biosaf Health. 2020 Mar;2(1):6-8
pubmed: 32562482
J Evid Based Med. 2020 May;13(2):93-101
pubmed: 32167245
Environ Health. 2005 May 10;4(1):6
pubmed: 15882472
Acad Emerg Med. 1998 Jun;5(6):613-7
pubmed: 9660289
Science. 2009 May 1;324(5927):572-3
pubmed: 19407164
Med Hypotheses. 2004;63(4):560-6
pubmed: 15324997
J Expo Sci Environ Epidemiol. 2007 Dec;17 Suppl 1:S55-66
pubmed: 17609687
CMAJ. 2016 May 17;188(8):567-574
pubmed: 26952529